Spago Nanomedical AB (publ) today announced the establishment of a Scientific Advisory Council (SAB) composed of scientific and clinical leaders in the fields of oncology and nuclear medicine. SAB will provide support and guidance in the clinical development of the Tumorad radiopharmaceutical program with drug candidate 177Lu-SN201. At first SAB consisted of three prominent members; Professor Sten Nilsson, Professor Kristian Pietras and Dr. Austin Smith.
“We are pleased to assign Austin, Kristian and Sten to the Spago Nanomedical Scientific Advisory Board for Tumorad. Together they provide a wealth of knowledge and experience in the development of new radionucleotide therapies for cancer. Their collective expertise will be critical as we progress Tumorad through its clinical development and regulatory phases, which recently began with clinical trial applications for phase I/IIa studies in patients with advanced cancer.said CEO Mats Hansen.
The SAB will help guide the future direction of Tumorad’s clinical development. Reviewing ongoing data and contributing medical and scientific knowledge, the Advisory Board will have a critical role in ensuring the Tumorad program can meet its goal of bringing new and valuable treatment options to the most appropriate patients. Additional members may be added to the Advisory Board as the program progresses.
The current members of Tumorad SAB are:
Professor Sten Nilsson
Sten is a specialist and emeritus professor of oncology in the Department of Oncology-Pathology, Karolinska, as well as a nuclear medicine specialist. Sten was responsible for study design and led the initial Xofigo clinical program™ (formerly Alfaradin™). Sten was previously chair of the Swedish Association of Oncologists (SOF) and Swedish Association of Nuclear Medicine (SFNM) and a member of the EANM Radionuclide Therapy Task Force. He has published more than 200 scientific articles.
Professor Christian Pietras
Kristian is a professor in Molecular Medicine at Lund University, specializing in translational cancer research as a link between basic science, clinical science and the pharmaceutical industry. Kristian has made important contributions in defining the tumor as a communication organ composed of various cell types that collectively underpin cancer development. Kristian has been a member and chairman of the Young Academy of Sweden, and is an elected member of the Royal Physiographic Society. He has published more than 100 research articles and patents.
Dr. Austin Smith
Austin is trained and qualified in Medical Oncology and Pharmaceutical Medicine. Austin is a graduate of the Royal College of Surgeons, Ireland and has a strong background in all aspects of Malignant Oncology and Hematology, along with Regulatory Science experience across Europe, the US, and the Asia-Pacific region, serving in senior and executive positions in biopharma. company. Austin is also a member of the Oncology Experts Group, representing the UK’s School of Pharmaceutical Medicine.